2.2 Compiler Design
3.3.4 Manipulation Instructions
1. Subjects on protease inhibitors were not included in the study.
2. Inability to perform oral glucose tolerance test on participants to exclude impaired glucose tolerance despite fasting normoglyceamia.
3. Insulin resistance was inferred rather than accurately measured in each study participants.
4. Inability to determine the body fat distribution with computerized tomography scan due to high cost of such.
112 REFERENCES
1. Federal Ministry of Health Nigeria (FMOH) . 2005 National HIV/Syphilis sero-prevalence sentinel survey among pregnant women attending antenatal clinics:
technical report, April 2006. Abuja, Federal Ministry of Health.
2. WHO/UNAIDS (2009). Global summary of the HIV/AIDS epidemic.December 2009. www.unaids.org
3. Currier JS. Cardiovascular risk associated with HIV therapy. J.Acquir. Immun. Defic.
Syndr.2002; 31: S16–S23.
4. Vigano A, Mora S, Testolin C, Beccio S, Schneider L, Bricalli D, Vanzulli A, Manzoni P, Brambilla P . Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J. Acquir.
Immun. Defic. Syndr.2003;32(5): 482-489.
5. Barbaro G: Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.Curr HIV Research 2006;4:79-85. 10.
6. Adelzon A Paula, Melissa CN Falcão and Antonio G Pacheco.Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects.J of AIDS Res and ther 2013; 10:32-36.
7. Sanusi M,Mahmoud U,Basil N,Okeahialam A.Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. Nigerian Medical Journal .2013;54(3): 185-190.
8 Worm SW, Lundgren JD. The metabolic syndrome in HIV. Best Pract Res ClinEndocrinol Metab.2011; 25:479–486.
9. Ayodele OE, Akinboro AO, Akinyemi SO, Adepeju AA, Akinremi OA, Alao CA.
Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome. Metab Syndr Relat Disord. 2012;10(5):373-9.
10. Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445-2453.
113
11. Onyebuchi CC, Ngige E N. National guideline for use of antiretroviral therapy.
Federal Ministry of Health 2013 page 1-3.
12. UNAIDS/WHO AIDS Epidemic Update: December 2007.www.unaids.org/Epi2006/
doc/report.html.Accessed 1st March 2014.
13. Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C.Excess mortality in patients with AIDS in the era of highly active antiretroviral therapy: temporal changes and risk factors.Clin Infect Dis.2010;51(8):947-56.
14. Smith D. Endocrine complications in HIV progression. AIDS Treatment News.
1991:140.
15. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipidemia in HIV disease.
Current Opinion in Lipidology. 2001;12:313-319.
16. Saves M, Raffi F, Capeau J. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 1396–405.
17. Hadigan C, Meigs JB, Corcoran C. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130–9.
18. Levitt NS, Bradshaw D. The impact of HIV/AIDS on type 2 diabetes prevalence and diabetes healthcare needs in South Africa: projections for 2010. Diabet Med 2006;
23: 103–4.
19. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy.J Acquir Immune Defic Syndr 2007;
46: 451–5.
20. Kalra S, Kalra B, Agrawal N, Unnikrishnan A. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr 2011; 2: 2.
21. Hasse B, Ledergerber B, Furrer H. Morbidity and aging in HIV-infected persons:
the Swiss HIV cohort study. Clin Infect Dis 2011; 53: 1130–9.
22. Samaras K. The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep 2012; 9: 206–17.
114
23. De Wit S, Sabin CA, Weber R. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care 2008; 31: 1224–9.
24. Tien PC, Barron Y, Justman JE. Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDs 2007; 21: 297–305.
25. Capeau J, Bouteloup V, Katlama C. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012; 26:
303–14.32.
26. Kantor R, Katzenstein DA, Efron B. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2: e112.
27. Brown TT, Cole SR, Li X. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179–84.
28 Reid MJ, Tsima BM, Kirk B.HIV and diabetes in Africa. Afr.J.Diabetes Med.
2012;20:2-6
29. Fleischman A, Johnsen S, Systrom DM. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab2007; 292: E1666–73.
30. WHO. Antiretroviral therapy for HIV infection in adults and adolescents:
recommendations for a public health approach. Geneva, Switzerland: WHO; 2010.
31. Carr A, Samaras K, Thorisdottir A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–9.
32. Carr A, Emery S, Law M. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet2003; 361: 726–35.
33. Daar ES, Tierney C, Fischl MA. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.Ann Intern Med2011; 154: 445–56.
34. Van der Valk M, Kastelein JJ, Murphy RL. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407–14.
115
35. Young J, Weber R, Rickenbach M. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther2005; 10: 585–91.
36. Taylor SA, Lee GA, Pao VY. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr2010; 55: 361–4.
37. Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.Curr Infect Dis Rep2004; 6: 471–82.
38. Rudich A, Ben-Romano R, Etzion S, Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.
Acta Physiol Scand2005; 183: 75–88.
39. Behrens G, Dejam A, Schmidt H. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63–70.
40. Bakari AG,Sani-Bello F,Shehu MS,Mai A,Aliyu IS,Lawal II.Antiretroviral therapy induced diabetes in a Nigerian. Afr Health Sci. 2007;7:133-135.
41. Unachukwu C,Uchenna D,Young E.Endocrine and metabolic disorders associated with Human immune deficiency virus infection. West Afr J of Med.2009;vol 28(1):293-299.
42. Fianko K.Dyslipidaemia and dysglycaemia in HIV –infected patients on highly active antiretroviral therapy in Kumasi metropolis. Sci Journ 2014;(4):56-58.
43. Huang JS, Lee D, Becerra K, Santos R, Barber E, Mathews WC.Body image in men with HIV.AIDS Patient Care STDS. 2006 Oct. 20(10):668-77.
44. Carr A, Cooper DA. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998;339:1296-1296
45. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
AIDS 2003;17:971-979
46 . Dube M, Zackin R, Tebas P. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine + lamivudine or
116
didanosine + stavudine combined with nelfinavir, efavirenz, or both: A5005s, a study of ACTG 384. Antivir Ther 2002;18:12-16
47. Martinez E, Mocroft A, Garcia-Viejo MA. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet
2001;357:592-598.
48. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS.
Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort.J Acquir Immune Defic Syndr
2002;30:440-447.
49. Bonnet E, Genoux A, Bernard J, Fauvel J, Massip P, Perret B. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy.Clin Chem Lab Med. 2007; 45(7):815-21.
50. Jacobson D. Knox T, Gorbach S, Wanke C. Prevalence of evolution and risk factor for fat atrophy and fat deposition in a cohort of HIV infected men and women. Clin.Infe.
Dis. 2005;40(12): 1837-1845
51. Mercier S.,Gueye N, Cournil A. Lipodystrophy and metabolic disorders in HIV-1- infected adults on 4- to 9-year antiretroviral therapy in senegal: a case-control study,”
Journal of Acquired Immune Deficiency Syndromes.2009;(2): 224–230.
52. Van Griensven O, L. de Naeyer, T. Mushi.High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda,”
Transactions of the Royal Society of Tropical Medicine and Hygiene.2007;(8):793–
798.
53. Pujari, A. Dravid, E. Naik.“Lipodystrophy and dyslipidemia among patients taking first-line, world health organization-recommended highly active antiretroviral therapy regimens in Western India,” Journal of Acquired Immune Deficiency Syndromes.2005;(2) 199–202.
54. Worm O, Kirk O. Andersen A. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. HIV Medicine.2002;(4) 239–246.
117
55. Lichtenstein, K. M. Delaney, C. Armon.“Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients,” Journal of Acquired Immune Deficiency Syndromes.2003;(1): 48–56.
56. Miller A. Carr, S. Emery.HIV lipodystrophy: prevalence, severity and correlates of risk in Australia,” HIV Medicine.2013;( 3):293–301.
57. Hansen B A, Lindegaard N, Obel O, Andersen H, Nielsen, and J. Gerstoft,
“Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population,” HIV Medicine.2006;(7): 38–45.
58. Cziraky MJ. Management of dyslipidaemia in patients with metabolic syndrome. J Am Pharm Assoc (Wash) 2004;44:478-88.
59. Ana V, Jelena K, Slavica S, Nada B, Milica V, Vesna S et al. Evaluation of different formulas for LDL-C calculation. Lipids in Health and Diseases 2010; 9:27
60. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486
61. Tekes-Manova D, Israeli E, Shochat T, Swartzon M, Gordon S, Heruti R. The Prevalence of Reversible Cardiovascular Risk Factors in Israelis aged 25-55 years.
IMAJ 2006;8:527-31.
62. Cullen P, Schulte H, Assmann G. The Munster Heart Study (PROCAM). Total mortality in middle aged men is increased at low total cholesterol and LDL cholesterol concentrations in smokers but not in non-smokers. Circulation 1997;96:2128-36.
63. Coronary heart disease mortality trends among whites and blacks-Appalachia and United States 1980-1993. MMWR Morb Mortal Wkly Rep 1998;47:1005-12.
64. Stamler J, Daviglus ML, Garside DB. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long term coronary, cardiovascular and all cause mortality and to longevity. JAMA 2000;284:311-21.
65. Scientific Steering Committee on behalf of the Simon Broome Register Group.
Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management. Atherosclerosis 1999;142:105-15.
118
66. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol lower risk of ischaemic heart disease?Br Med J 1994;308:367-72.
67.
68.
69.
.
70.
71.
72.
73.
Friis-Moller N, Weber R, Reiss P. Cardiovascular disease risk factors in HIV patients -- association with antiretroviral therapy: results from the DAD study. AIDS
2003;17:1179-1193
Riddler SA, Smit E, Cole SR. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-2982
Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-1052
Christeff N, Melchior JC, de Truchis P, Perronne C, Gougeon ML. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 2002;32:43-50
Matthews GV, Moyle GJ, Mandalia S, Bower M, Nelson M, Gazzard BG. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. J Acquir Immune Defic Syndr 2000;24:310-315
Van der Valk M, Kastelein JJ, Murphy RL. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414.
Schmitz M, Michl GM, Walli R. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 2001;26:225-235
74. Shor-Posner G, Basit A, Lu Y.Hypocholesterolaemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med.1993;
94:515-519.
75. Francis M, Awah O, Onyinye A.Effect of highly active anti-retroviral therapy on lipid profile in a human immunodeficiency virus infected Nigerian population.Afri J of Biochem Res.2011;(9):282-286.
119
76. Isezuo S, Makusidi M.Metabolic dysfunctions in non –antiretroviral treated HIV/AIDSpatients.NigJ of Clin practice.Dec.2009;(4):375-378 .
77. Iffen TS, Efobi HU, Ussoro CA, Udonwa NE. Lipid profile of HIV patients attending University of Calabar Teaching Hospital, Calabar Nigeria. World J of Med Scie.2010;(4):89-93.
78. Adewole O, Eze S, BetikuY, Anteyi E, Ajuwon Z, Erhabor G. Lipid profiles in HIV/AIDS patients in Nigeria.Afr Health Sci.June2010;10(2):144-149
80. Florescu D, Kotler D. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients.Antiviral Therapy 2007; 12(2): 149–162
81 Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy.Lancet. 2005;365:1333-46
82. Saad MF, Knowler WC, Pettit DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989;1:1356–1359
83. Henderson M, Rabasa-Lhoret R, Bastard JP, Chiasson JL, Baillargeon JP, Hanley JA.
et al. Measuring insulin sensitivity in youth: How do the different indices compare with the gold-standard method?Diabetes Metab 2011; 37: 72–78.
84. Lebovitz HE.Clinician’s Manual on Insulin Resistance, London: Science Press Ltd;
2002 Vol. 1. p. 5.
85. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2013; 26:3320–3325.
86. Ezenwaka CE, Akanji AO, Akanji BO, Unwin NC, Adejuwon CA. The prevalence of insulin resistance and other cardiovascular disease risk factors in healthy elderly southwestern Nigerians. Atherosclerosis 2007;128:201–211
87. Ford ES,Giles WH.A comparison of the prevalence of the metabolic syndrome using two proposed definitions.Diabetes Care2004; 26:575–581.
120
88. Hommes MJ, Romijn JA, Endert E,Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men.Metabolism.2009; 40:651–656.
89. Samaras K, Gan SK, Peake PW, Carr A, Campbell LV. Proinflammatory markers, insulin sensitivity, and cardiometabolic risk factors in treated HIV infection. Obes (Silver Spring.2009; 17:53–9.
90. Gerschenson M,BrinkmanK. Mitochondrial dysfunction in AIDS and its treatment.Mitochondrion2004; 4:763–777.
91 Limone P, Biglino A, Valle M .Insulin resistance in HIV infected patients:relationship with pro-inflammatory cytokines released by peripheral leukocytes.J Infect.2003;47:52-58.
92. Miguel A. Guillen, Fernando A. Mejia, Jaime Villena, Christie G. Turin,Cesar P.
Carcamo et al.Insulin resistance by homeostasis model assessment in HIV-infected patients on highly active antiretroviral therapy: cross-sectional study.Diabetol Metab Syndr. 2015; 7: 49
94. The Data Collection on Adverse Events of Anti-HIV Drugs(DAD) Study Group Combination.Antiretroviral Therapy and the Risk of Myocardial Infarction.N Engl J Med 2003;349:1993-2003.
95. Whitworth JA.World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.J Hypertens.2003;
21(11):1983–1992.
96. Sola Aoun, Emilio Ramos. Hypertension in the HIV infected patients. Current Hypertension Reports.2000; 2(5):478-481.
97. Dillon C, Bruno R, Garzaniti A.Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens2003; 21(7):
1377–1382.
121
98. Gazzaruso C, Sacchi P, Garzaniti A, Fratino P, Bruno R, Filice G. Prevalence of metabolic syndrome among HIV patients. Diabetes Care,2012; 25:1253–1254.
99. Bergersen B, Sandvik L, Dunlop O., Birkeland K., Bruun J. Prevalence of Hypertension in HIV-Positive Patients on Highly Active Retroviral Therapy (HAART) Compared with HAART-Naive and HIV-Negative Controls: Results from a Norwegian Study of 721 Patients. Eur J Clin Microbiol Infect Dis 2003;22:731–36.
100. Jerico C, Knobel H, Montero M. Hypertension in HIV-Infected Patients: Prevalence and Related Factors. Am J Hypertens.2005; 18:1396–401.
101. Schutte AE, Schutte R, Huisman HW. Are behavioural risk factors to be blamed for the conversion from optimal blood pressure to hypertensive status in Black South Africans? A 5-year prospective study.Int J Epidemiol.2012; 41:1114–23.
102. Friis-Moller N, Weber R, Reiss P. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study.
AIDS.2003; 17:1179–1193.
103. Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone N. Hypertension is common among HIV-infected persons, but not associated with HAART. J of the Int Assoc of Physic in AIDS Care (JIAPAC).2012; 11(1), 20–25.
104. Baekken M, Os I, Sandvik I, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens 2010; 26:2126–2133.
105. Reaven GM. Role of insulin resistance in human disease. Journ of Diab.1988;
37:1595–1607.
106. Bonora E, Kiechl S, Willeit J. Prevalence of insulin resistance in metabolic disorders:
the Bruneck Study. Diabetes,1998; 47(10):1643–9
107. Paul L.Huang. A comprehensive definition for metabolic syndrome.Dis Model Mech.2009;2(5):231-237.
108. Palella F, Wang Z, Chu H.Correlates and prevalence of the metabolic syndrome over time in the Multicenter AIDS Cohort Study.Presented at: Third International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro: International Association of Physicians in AIDS Care (IAPAC); 2006, 12:9
122
109. Sales S, Campa A, Makhema J, Dusara P, Tsalaile L, Burns P et al. Metabolic Syndrome in HIV + Asymptomatic Adults in Botswana, Africa. The Journ. of the Fed. of Ame. Soc. for Exper. Biol. 2008;23:918,4
110. Mhlabi D. Metabolic syndrome among people with Human Immunodeficiency Virus on Anti-retroviral Therapy at Princess Marina Hospital in Gaborone-Botswana.Thesis (MPH)); University of Limpopo (Medunsa Campus), 2011.
111. Botha S, Fourie C, Johannes M, van Rooyen, Kruger A, Schutte A. Cardiometabolic Changes in Treated Versus Never Treated HIV-Infected Black South Africans: The PURE Study. Heart Lung Circulation 2013 ;(7):019-021.
112. Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M et al. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med Journal.2012; 13:43-46
113. Diouf Assane, Cournil Amandine, Ba-Fall Khadidiatou, Nd`eye Fatou Ngom-Gu`eye et al. Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment since 1998 in Senegal: Prevalence and Associated Factors-Clinical Study, International Scholarly Research Network (ISRN) AIDS 2012, Article ID 621565: 1–
8.
114. Araoye MO. Research Methodology with Statistics for Health and Social Sciences.
1st Edition. Nathadex publishers, Ilorin, 2004: 116-118.
115. Iwuala SO, Lesi OA, Fasanmade OA, Sabir A, Olamoyegun MA, Okany C.C.
Prevalence of and risk factors for Lipoatrophy in patients with HIV infection in Nigeria.AIDS Res Treat.2015;2015: 102638
.
116 .Radikova Z,Koska J,Huckova M.Insulin sensitivity indices:a proposal of cut off points for simple identification of insulin resistant subjects.Experiments and Clin. Endo. and Diab.2006;114(5):249-256.
117 Expert committee on the diagnosis and classification of Diabetes Mellitus:Report of the expert committee on the diagnosis and classification of diabetes mellitus.Diabetes care. 1997;20:1183-1197
123
118. WHO technical report series. The use and interpretation of Anthropometry.WHO1995;8(54):9
119. Fate Bashir Abaid. Cardiometabolic effects of antiretroviral treatment in the Cape Wineland region of South Africa.Thesis(MSc);Stellenbosch University,2016.
121. Cattelam AM,Trevenzoli M, Sasset L, Cadrobbi P. Indinavir and systemic hypertension.J of AIDS2001;15:805-7.
123. Esposito FM, Coutsoudis A, Visser J, Kindia G. Changes in body composition and other anthropometric measures of subjects on Highly Active Antiretroviral therapy. A pilot study in Kwazulu-Nata, South Africa .S.afr.J .HIV Med.2012;34(4);123-128 124. Silver M, Skolnik P, Gorbach S. The effect of HAART on weight and body
composition in HIV infected patients. AIDS 1998;12:1645-1651.
125. Multimura E, Stewart A, Rheeder P, Crowther N.J. Metabolic functions and the prevalence of lipodystrophy in a population of HIV – infected African subjects receiving highly active antiretroviral therapy. J Acqur Immune Defic Syndrome 2007;
46: 451- 455.
126. Manuthu E.M, Joshi M.D, Lue G.N, Karari E. Prevalence of dyslipidaemia and dysglyceamia in HIV infected patients. East Afr. Med J. 2008; 85: 10-17.
127 Daves J.A, Lambert E.V, Badri M, West S, Maartens G, Levitt N.S. Effect of non nucleoside reverse transcriptase inhibitor based antiretroviral therapy on dysglycaemia and insulin sensitivity in South African HIV infected patients. J Acqur Immune Defic. Syndrome 2001. 57;62: 284-289
124
128. Shrivastav S,Kino T,Chrousos GP,Kopp JB. Hiv Vpr binds and inhibits PPARγ:implications for HIV-associated insulin resistance and lipodystrophy. Journ.
of Diab.2005;54(1)23-31.
129. Kino T, Gragerov A, Slobodskya O, Tsopanomichalou M, Chrousos GP, Pavlakis GN.
Human immunodeficiency virus type 1 accessory protein Vpr induces transcription of the HIV-1 and glucocorticoids –responsive promoters. Journ of Virol.2002;76(19) 9724- 9734.
130. Obirikorang C, Quaye L, Osei-Yeboah O, Asare I. Prevalence of MS among HIV infected patients in Ghana; a cross sectional study.Niger Med.J.2016;57(2):86-90.
125 APPENDIX I CONSENT FORM
I ________________________________________ have heard the details of the study titled The effect of Highly Active Antiretroviral Therapy on the Metabolic parameters of HIV/AIDS patients in Abeokuta South-West Nigeria explained to me by Dr.Alalade Boladale A., the coordinator of this research. I have had the opportunity to read through the form, ask questions which have been answered to my satisfaction.
I understand the purpose of this study which is being carried out at the Department of Community Medicine, Federal Medical Centre Abeokuta. The risk and benefits of the study have also been explained and I reserve the right to withdraw from the study without any adverse effect on me. I am assured that my identity is protected.
I hereby give my consent to participate fully in the study including clinical examination and necessary studies on my blood sample.
Name of Participant ________________________________________
Signature & Date ________________________________________
Name of Witness ____________________________________________
Signature & Date ____________________________________________
I confirm that I have given an explanation on the purpose, benefits, nature and hazards of this study to the above named participant who has agreed to participate.
Name of Researcher: _______________________________________________
Signature and Date: ________________________________________________